NCT06120764 Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
| NCT ID | NCT06120764 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baskent University |
| Condition | Chemotherapy-induced Nausea and Vomiting |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-10 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-11-10 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients. Participants will receive either guided imagery+routine care or routine care. The researchers will compare nausea and vomiting and vital signs between groups.
Eligibility Criteria
Inclusion Criteria: * 7 to 18 years old, * who will receive intravenous chemotherapy, * no cognitive or neurological disease that would prevent communication, * receiving a chemotherapy protocol with a high or moderate emetogenic effect according to the MASCC/ESMO Antiemetic Guideline Classification, * no verbal, visual and auditory communication disabilities (ability to speak Turkish, no mental deficiency), * children whose parents and themselves volunteered to participate in the study Exclusion Criteria: * Children receiving radiotherapy, * taking ginger powder or vitamins to reduce nausea, * children who did not want to participate in the study
Contact & Investigator
Ayşe Ay, RN, PhD
PRINCIPAL INVESTIGATOR
Baskent University
Frequently Asked Questions
Who can join the NCT06120764 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 18 Years, studying Chemotherapy-induced Nausea and Vomiting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06120764 currently recruiting?
Yes, NCT06120764 is actively recruiting participants. Contact the research team at ayse0526@gmail.com for enrollment information.
Where is the NCT06120764 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06120764 clinical trial?
NCT06120764 is sponsored by Baskent University. The principal investigator is Ayşe Ay, RN, PhD at Baskent University. The trial plans to enroll 40 participants.